We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s generic drug program would receive about $56.2 million under President Bush’s proposed fiscal 2006 budget — the same figure it received in the fiscal 2005 budget.
The number of domestic field inspections conducted by the FDA’s Office of Regulatory Affairs (ORA) would decrease from 2,815 in fiscal 2005 to 2,668 in fiscal 2006, with the biggest drop coming in good manufacturing practice (GMP) inspections, according to figures contained in the FDA’s proposed budget request.
The FDA's drug safety efforts would receive an additional $6.5 million under President Bush's proposed 2006 budget, which also recommends giving the agency $747 million for human drugs and biologics programs -- an overall increase of $26 million from fiscal 2005 levels.
One of the FDA’s major goals for 2005 and 2006 is to speed marketing approval times for generic drugs, but the agency will have to accomplish that task without much of an increase in funding for its generic drug program.
President Bush's proposed fiscal 2006 budget would boost the FDA's drug safety efforts by an additional $6.5 million, giving the agency a total of $747 million for human drugs and biologics programs -- an overall increase of $26 million from fiscal 2005 levels
The FDA will get more money from Congress than the agency requested to ensure adequate flu vaccine production, but less money than it sought to move its Center for Drug Evaluation and Research (CDER) offices to a new campus in Maryland, according to the mammoth fiscal 2005 spending bill.
The FDA will get less money from Congress than it sought to move its Center for Drug Evaluation and Research (CDER) offices to a new campus in Maryland, but more than the agency requested to ensure adequate flu vaccine production, according to the mammoth fiscal 2005 spending bill.
Congress should fully fund the FDA’s request for $100 million so it can go beyond the nation’s current reliance on egg-based flu vaccine, according to FDA acting Commissioner Lester Crawford.
Senate appropriators have set aside $15 million for government research on the comparative effectiveness of prescription drug products, marking the first time federal funding would be used for such a purpose.